This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
What's in Store for Emergent (EBS) This Earnings Season?
by Zacks Equity Research
On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.
Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.
Glaxo (GSK) Q3 Earnings Top, Vaccines Segment on Recovery Path
by Zacks Equity Research
Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.
Update on the COVID Vaccine Race
by John Blank
A 2021 Macro Recovery is About This, Alone.
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q3 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q3 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.
Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More
by Zacks Equity Research
Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.
Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.
Merck (MRK) Beats on Q3 Earnings & Sales, Updates Guidance
by Zacks Equity Research
Merck (MRK) increases earnings guidance while tightening sales outlook for the year. Shares up in pre-market trading.
Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Bayer (BAYRY) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 3.
Will AbbVie (ABBV) Q3 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Investors will focus on any recovery in AbbVie's (ABBV) sales amid the coronavirus pandemic when it reports third-quarter results.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon
by Zacks Equity Research
Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.
Aptinyx (APTX) Surges on Promising Stress Disorder Study Data
by Zacks Equity Research
Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.
Stock Market News for Oct 20, 2020
by Zacks Equity Research
Benchmarks closed sharply lower on Monday as possibilities over a fresh stimulus package remain doubtful before the presidential election.
Weekly ETF Roundup: Broad U.S. Equity Tops, Biotech Flops
by Sweta Killa
ETFs overall gathered about $18.5 billion capital last week, bringing year-to-date inflows of $352.6 billion, ahead of the $211.7 billion seen at this same time a year ago.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology
Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
Pandemic Surges, Stimulus Fades: ETF Strategies to Follow
by Sweta Killa
Volatility has once again been playing foul in the stock market due to resurgent COVID-19 infections and fading hopes of additional stimulus. Investors should follow some techniques to minimize volatility in their portfolio.